WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Britain's new bonkers EV: Callum Skye is an £80k electric buggy built in Warwickshire
China develops first 100 kg vehicle
King Charles and Queen Camilla could miss super
Scheffler looks to the weekend after PGA Championship arrest
OpenAI pauses ChatGPT voice after Scarlett Johansson comparisons
Brown v. Board: Even with school choice, some Black families find options lacking
9 killed in northwest China's traffic accident
Nadal returns to Roland Garros to practice amid doubts over fitness and form
Javier Báez has 5 RBIs, Tigers knock out 17 hits in 13
Russian theater director and playwright go on trial over a play authorities say justifies terrorism
Argentine president begins unusual visit to Spain, snubbing officials and courting the far